Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Mebias Discovery, Inc logo — Mining the Full Potential of GPCR Drugs

Mebias Discovery, Inc

Mining the Full Potential of GPCR Drugs

Founded 2015 4 employees Series Unknown Total: $4.13M Gaming, Mobile

General Information

Company Name Mebias Discovery, Inc
Founded Year 2015
Founders / Decision Makers
Team member
Employees 4
Industries Gaming, Mobile
Funding Stage Series Unknown
Social

Get notified when Mebias Discovery, Inc moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Mebias Discovery, Inc

Mebias Discovery, Inc. is a biotech startup with a vision to unlock the full potential of GPCR drugs, as reflected in its slogan, "Mining the Full Potential of GPCR Drugs." Founded in 2015, Mebias has developed a groundbreaking platform to discover next-generation GPCR drugs without on-target side effects. Their expertise lies in G-protein Coupled Receptor (GPCR) therapeutics, which constitute approximately 30% of current prescribed drugs. Mebias leverages its understanding of protein dynamics and has access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – to identify agonists lacking in other methodologies. The company boasts a series of biased mu opioid receptor scaffolds, including a clinical stage compound, and their platform significantly reduces time and costs for delivering optimized leads. Mebias' initial focus areas are CNS/Pain, OUD, Metabolic, and Inflammatory related disorders. Expertise/Assets: The company excels in the rapid identification and optimization of IND candidates devoid of on-target adverse effects. Mebias also offers a differentiated mu-opioid receptor agonist (MEB-1170) for the treatment of OUD and pain, lacking respiratory depression/GI motility issues/tolerance, and without demonstrating potential for abuse liability. Business Proposal: Mebias is seeking co-development and/or licensing opportunities for its mu-opioid drug candidates, as well as research funding/collaboration for lead discovery of additional targets in selected disease areas. The company has recently received a $630.68K Venture Round investment on 23 September 2022.

Taxonomy: GPCR therapeutics, Pathway-selective drugs, Drug discovery platform, Biased ligand drugs, Conformation-based SAR, Protein dynamics, Nuclear magnetic resonance, IND candidates, Mu-opioid receptor, Neuropathic pain, Nociceptive pain, Lead discovery, CNS disorders, Metabolic disorders, Inflammatory disorders

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 23 Sep 2022
Venture Round •••••• 2
Investor
•••• •••• 		14 Oct 2019
Venture Round •••••• 1
Investor
14 Feb 2017
Venture Round •••••• 1
Investor
23 Sep 2016
Seed Round •••••• 1
Investor
01 Mar 2016

Mebias Discovery, Inc Alternatives & Competitors

Mebias Discovery, Inc vs
INVENT Pharmaceuticals
INVENT Pharmaceuticals United States

Transforming molecules to medicines

1 employees
Biotechnology, Health Care
Mebias Discovery, Inc vs
ALGOMEDIX, INC.
ALGOMEDIX, INC. United States

2 employees
Biotechnology, Health and Wellness
Mebias Discovery, Inc vs
Design Pharmaceuticals Inc.
Design Pharmaceuticals Inc. United States

Boundless GPCR drug discovery

Seed
3 employees
Biotechnology, Health Care

FAQ About Mebias Discovery, Inc

Mining the Full Potential of GPCR Drugs
Mebias Discovery, Inc was founded in 2015.
Mebias Discovery, Inc operates in the following industries: Gaming, Mobile.
Mebias Discovery, Inc has approximately 4 employees.
Mebias Discovery, Inc has completed 5 funding rounds, raising a total of $4.13M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Mebias Discovery, Inc include INVENT Pharmaceuticals, ALGOMEDIX, INC., Design Pharmaceuticals Inc., Rayca Precision. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Mebias Discovery, Inc and INVENT Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Mebias Discovery, Inc and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes